Welcome to our dedicated page for Reshape Lifesciences news (Ticker: RSLS), a resource for investors and traders seeking the latest updates and insights on Reshape Lifesciences stock.
Reshape Lifesciences Inc. (RSLS) is a medical device innovator focused on non-surgical solutions for weight management and metabolic health. This page provides investors and healthcare professionals with essential updates on corporate milestones, product developments, and clinical advancements.
Access timely announcements including regulatory approvals, strategic partnerships, and clinical trial outcomes. Our curated news feed helps stakeholders track the company’s progress in advancing alternatives to invasive obesity treatments and diabetes management technologies.
Key coverage areas include product innovation updates, financial disclosures, and market expansion initiatives. Bookmark this page for structured access to RSLS’s evolving role in the medical device sector, with neutral reporting suitable for both casual observers and professional analysts.
ReShape Lifesciences (RSLS) has announced a securities purchase agreement with an institutional investor for a registered direct offering of 2,884,615 shares of common stock at $0.26 per share and 2,500 shares of Series D Preferred Stock. The offering is expected to close by November 9, 2022, with total gross proceeds expected to be approximately $750,000. The proceeds will be used for commercialization, clinical development, and working capital. Additionally, existing warrants will be amended to reduce the exercise price to $0.30 per share.
ReShape Lifesciences (Nasdaq: RSLS) will release its third quarter financial results on November 14, 2022, before market opening. A corporate update will accompany these results. Following the announcement, management will host a conference call at 8:00 am ET, available via their website. ReShape Lifesciences specializes in weight loss and metabolic health solutions, offering products like the FDA-approved Lap-Band® Program and the investigational ReShape Vest™ System, aimed at treating obesity and metabolic diseases.
ReShape Lifesciences (Nasdaq: RSLS) presented data on its Diabetes Bloc-Stim Neuromodulation™ (DBSN™) device at the Obesity Society Annual Meeting in San Diego. The device demonstrated safety and efficacy in a swine model of type 2 diabetes, reducing glucose variability during tests. The DBSN™ device employs bioelectronic modulation to enhance insulin production while blocking glucose release from the liver. The CEO highlighted the technology's potential in treating diabetes and reducing medication dependence. The company continues development with a focus on metabolic disorders.
SAN CLEMENTE, Calif., Nov. 02, 2022 – ReShape Lifesciences (Nasdaq: RSLS) announces that CEO Paul F. Hickey and CFO Tom Stankovich will present at the Q4 Investor Summit on November 14 at 1:30 p.m. ET. They will highlight the next-generation Lap-Band® program and the reshape
ReShape Lifesciences (Nasdaq: RSLS) announced updated guidelines from the ASMBS and IFSO for metabolic and bariatric surgery, which now recommend surgery for individuals with a BMI of 35 or more, regardless of comorbidities. The Lap-Band® is highlighted as the only FDA-approved device for weight reduction in this category. The new guidelines may significantly increase the number of eligible patients, enhancing access to weight loss procedures, particularly for those with a BMI over 30 and related health issues. These changes are expected to positively impact demand for Lap-Band® procedures and potentially boost revenues.
ReShape Lifesciences (Nasdaq: RSLS) announced promising results for its Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system, detailed in the journal Frontiers in NeuroScience. The study showed that DBSN™ effectively improved glycemic control in type 2 diabetic rat and swine models by blocking and stimulating vagus nerve signals. The therapy may reduce insulin resistance while increasing insulin release, positioning it as a novel, adjustable treatment for type 2 diabetes. This research was supported by NIH Small Business Innovation Research grants, confirming its potential impact on diabetes management.
ReShape Lifesciences (Nasdaq: RSLS) announced that the American Society for Metabolic and Bariatric Surgery (ASMBS) has issued a new Consensus Statement on the management of Lap-Band® patients. This consensus, developed by 39 expert surgeons, includes 34 statements focused on aftercare practices and the efficacy of Lap-Band® as a weight loss solution. The report emphasizes the importance of behavioral health and nutrition in post-surgery care, aligning with ReShape's reshapecare™ program designed to support patients through virtual health coaching.
ReShape Lifesciences (Nasdaq: RSLS) has received a $300,000 Small Business Innovation Research (SBIR) grant to develop the Diabetes Bloc-Stim Neuromodulation™ (DBSN™) device for treating hypoglycemia. This device uses proprietary vagus nerve block technology in conjunction with a continuous glucose monitor. The funding will enable further development of the device, which aims to enhance glucose management and reduce hypoglycemia risks in diabetes patients. The technology is backed by 48 patents and has shown safety and efficacy in previous studies.
ReShape Lifesciences (Nasdaq: RSLS) announced participation in one-on-one meetings with institutional investors at the A.G.P. Virtual MedTech Conference on September 21, 2022. The company, focused on weight loss and metabolic health, offers various solutions, including the FDA-approved Lap-Band® Program and the ReShape Vest™ System. For more information, interested investors can contact their A.G.P. representative.
ReShape Lifesciences (Nasdaq: RSLS) has appointed Nick Ansari as Senior Vice President of Global Commercial Operations, effective September 6, 2022. Ansari brings over 30 years of experience in developing sales initiatives within the medical device industry, having previously held key roles at Enteromedics, Johnson & Johnson, and Medtronic. His leadership is expected to enhance sales growth for the Lap-Band® and strengthen ReShape's market presence globally. The Lap-Band® has successfully helped over one million patients achieve weight loss over the past two decades.
FAQ
What is the current stock price of Reshape Lifesciences (RSLS)?
What is the market cap of Reshape Lifesciences (RSLS)?
